CU6's Principal Activity is the clarity is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-60.34%|
Clarity Pharmaceuticals Ltd (CU6) is a clinical stage radiopharmaceutical company. The company is a global leader in Targeted Copper Theranostics (TCT), developed with their proprietary SAR Technology platform. The group also has a range of products in clinical trials which address both prostate cancer and breast cancer as well as neuroendocrine tumours (NETs) and neuroblastoma of cancer.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Mr Robert Bain Thomas||Non-Executive Director||Aug 2021||
Mr Robert Bain Thomas
Mr Thomas has a background in financial services and capital markets and has experience in mergers & acquisitions and capital markets including advising on the IPOs of the Commonwealth Bank of Australia and Qantas. Mr Thomas is the former CEO of County NatWest Securities and the former CEO (and then Chairman) of Citi Corporate and Investment Bank Australasia. Mr Thomas has also held the position of Chairman at Australian Wealth Management Ltd (ultimately IOOF Ltd), TAL (Australia's largest life insurance company) and the previously ASX-listed company HeartWare International Inc. Mr Thomas is the Chairman of AusBio Ltd, Grahger Retail Securities Pty Ltd and ASX-listed Starpharma Holdings Limited, and is a non-executive director of Biotron Limited and O'Connell Street Associates. He is a past non-executive director of Reva Medical Inc. and Virgin Australia. He is also served as chair of Risk Committee of CU6.
|Dr Colin David Biggin||Chief Executive Officer,Managing Director||Oct 2019||
Dr Colin David Biggin
Chief Executive Officer,Managing Director
Dr Biggin has over 15 years of radiopharmaceutical development and commercialisation experience. Dr Biggin previously served with Algeta ASA during the development and commercialisation of its product Xofigo (radium-223 dichloride) for metastatic prostate cancer, which was approved by the FDA in 2013. Prior to joining the Company, Dr Biggin also consulted to a range of biotech and large pharmaceutical companies developing radiopharmaceuticals.
|Dr Charles Gillies O'Bryan-Tear||Non-Executive Director||Apr 2019||
Dr Charles Gillies O'Bryan-Tear
Dr O'Bryan-Tear has over 30 years of experience in the pharmaceutical industry in clinical development, medical management and commercial roles. He has held senior leadership roles in large and small pharmaceutical and biotech companies in the US and Europe and has been involved in multiple product approvals. He was previously the Chief Medical Officer of Algeta ASA. Dr O'Bryan-Tear has been an adviser to several US and European biotech companies and is a member of the Scientific Advisory Boards of Audentes, Inc. (US) and Fusion Pharmaceuticals Inc. (Canada).
|Dr Thomas Ramdahl||Non-Executive Director||Mar 2019||
Dr Thomas Ramdahl
Dr Ramdahl is a pharmaceutical executive with over 20 years of clinical and development experience. In 2001, he became President and the first CEO of Algeta ASA. When Dr Ramdahl joined Algeta, he was one of six employees and he was involved in serving in several senior positions within the company through to and post the acquisition of Algeta by Bayer AG in 2014. Dr Ramdahl has authored more than 40 publications and is a co-inventor of several patents. Dr Ramdahl currently serves as Chairman of Precirix (Belgium) and AppSens AS (Norway).
|Dr Christopher Graham Roberts||Non-Executive Director||Mar 2016||
Dr Christopher Graham Roberts
Dr Roberts has over 40 years of experience in the medical innovation space and has served on the boards of a number of ASX-listed companies during his career. Dr Roberts was previously the CEO of ASX-listed company Cochlear Limited and Chairman of ASX-listed company Sirtex Medical Ltd. Dr Roberts was also Executive VicePresident and a director of the dual-listed (ASX and NYSE) company ResMed Inc., a global sleep disorder treatment company. Dr Roberts is Chairman of the ASX-listed company Oncosil Ltd. He is also served as member of Risk Committee of CU6.
|Dr Alan John Taylor||Executive Chairman,Executive Director||Nov 2013||
Dr Alan John Taylor
Executive Chairman,Executive Director
Dr Taylor has approximately 15 years of investment banking experience focused mainly on the life sciences sector, and also has experience in capital raisings, mergers and acquisitions, and general corporate advisory. Prior to joining Clarity, Dr Taylor was an Executive Director of Inteq Limited, a boutique Australian investment bank.
|Ms Rosanne Elizabeth Robinson||Non-Executive Director||Oct 2010||
Ms Rosanne Elizabeth Robinson
Ms Robinson has experience in the nuclear field and has over 25 years of experience in both governance and management roles in public and private companies and government. Ms Robinson is the General Manager of Business Development at Australian Nuclear Science and Technology Organization. Ms Robinson also has experience of the nuclear medicine industry and knowledge of most recent changes in the sector. She is also served as member of Risk Committee of CU6.
|Mr Robert Cochrane Vickery||Chief Financial Officer,Company Secretary||N/A|
CU6 directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|31/05/22||Thomas Ramdahl||Buy||+120,000||$0.483||$57,960||On-market trade|
|26/05/22||Robert Thomas||Buy||+100,000||$0.439||$43,905||On-market trade|
|24/12/21||Colin Biggin||Issued||200,000||$0.75||$150,000||Exercise of options|
|24/12/21||Colin Biggin||Exercise||200,000||$0.75||$150,000||Exercise of options|
The current holdings of CU6 directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
No Substantial Shareholders for CU6 in our database.
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|25-08-21||Alan John Taylor||14,066,660||--||5.49|
|25-08-21||Matthew John Harris||14,078,620||--||5.50|
|25-08-21||Charles Waite Morgan||18,593,040||--||7.26|
|25-08-21||Cabbit Pty Ltd||17,911,280||--||6.99|
|25-08-21||Genesis Care Pty Limited||15,362,700||--||6.00|
|25-08-21||Asia GCMIV Holdings II Pte Ltd||15,362,700||--||6.00|
|25-08-21||TM Ventures Pty Ltd||18,788,460||--||7.34|
|25-08-21||Asia Pacific Healthcare Investments Limited||15,362,700||--||6.00|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.